Tert-butyl 3-(2-methoxy-2-oxoethyl)-4-oxopiperidine-1-carboxylate | 694450-89-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Tert-butyl 3-(2-methoxy-2-oxoethyl)-4-oxopiperidine-1-carboxylate
• CAS: 694450-89-0
• 化学式: C₁₃H₂₁NO₅
• 分子量: 271.313
• InChiKey: GPRQZXMNJPBEMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 在 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 Tert-butyl 3-(2-methoxy-2-oxoethyl)-4-oxopiperidine-1-carboxylate
  参考文献：
  名称：

  Pilot Plant Preparation of tert-Butyl-4-(2-hydroxyethyl)-4-(pyrrolidin-1-yl)-piperidine-1-carboxylate, An Intermediate of Novel Antiarteriosclerotics, Via a Safe, Scalable Reformatsky-Type Reaction

  摘要：

  Reported here is a safe, scalable process via a Reformatsky-type reaction of iminium salt (4) followed by Red-Al reduction giving tert-butyl-4-(2-hydroxyethyl)-4-(pyrrolidin-1-yl)-piperidine-1-carboxylate (6), an intermediate of novel antiarteriosclerotics (1). The key points of this safe process are the use of trifluoroacetic acid (TFA) for the iminium salt formation, vigorous stirring for the Reformatsky reaction, and slow addition of methyl bromoacetate. Pilot manufacturing on the 500 L scale was achieved.

  DOI：

  10.1021/op2001723

文献信息

• Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme
  申请人：——

  公开号：US20040122005A1

  公开（公告）日：2004-06-24

  The present application describes novel isoxazoline of formula I or II: 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R 1 , R 2 , R 3 , R 4 , Z, U, X, Y, Z a , and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), or a combination thereof.

  本申请描述了新型异噁唑烷式I或II的化合物：1或其药学上可接受的盐或前药形式，其中A、R1、R2、R3、R4、Z、U、X、Y、Za和n在本说明书中有定义，可用作基质金属蛋白酶（MMP）、TNF-α转化酶（TACE）或两者的抑制剂。
• US7125870B2
  申请人：——

  公开号：US7125870B2

  公开（公告）日：2006-10-24
• [EN] ISOXAZOLINE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME<br/>[FR] DERIVES D'ISOXAZOLINE COMME INHIBITEURS DE METALLOPROTEASES MATRICIELLES ET/OU D'ENZYME DE CONVERSION DE TNF- DOLLAR G(A)
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2004043349A2

  公开（公告）日：2004-05-27

  The present application describes novel isoxazoline of formula I or II: [TWO CHEMICAL STRUCTURES]or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-a converting enzyme (TACE), or a combination thereof.
• [EN] PHTHALAZINONE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF<br/>[FR] DÉRIVÉ DE PHTALAZINONE, SON PROCÉDÉ DE PRÉPARATION ET UTILISATION PHARMACEUTIQUE
  申请人：SHANGHAI HENGRUI PHARM CO LTD

  公开号：WO2012019426A1

  公开（公告）日：2012-02-16

  The present invention relates to a phthalazinone derivative, and a preparation method and a pharmaceutical use thereof, and specifically the present invention relates to a new phthalazinone derivative represented by a general formula (I), a preparation method, a pharmaceutical composition containing the derivative, and a use thereof as a therapeutic agent and especially a poly (ADP-ribose) polymerase (PARP) inhibitor.